MINNEAPOLIS, July 25, 2016 (PR NEWSWIRE) – ARKRAY USA, Inc., a leader in diabetes care products, announced today the launch of TechLITE Pen Needles. Pen needles are used with injection pen devices for the subcutaneous injection of insulin by those with insulin-dependent diabetes.

“The addition of the TechLITE Pen Needles to our family of diabetes products allows ARKRAY to further meet the needs of people with diabetes who require insulin injections,” said ARKRAY USA President Jonathan Chapman. “TechLITE Pen Needles are high quality, easy to use and provide reliably smooth and consistent insulin delivery at an affordable price.”

TechLITE Pen Needles combine thin-wall technology with precise lubrication techniques and pinpoint sharpening to provide a safe and precise insulin injection experience and are available in multiple gauges to meet individual needs.

Diabetes, or diabetes mellitus, is a metabolic type of disease in which affected people have high blood glucose (blood sugar), either because insulin production is inadequate (Type 2), or because the islet cells in the pancreas no longer produce insulin (Type 1, sometimes referred to as juvenile diabetes). The ADA estimates that more than 30 million Americans suffer from either Type 1 or Type 2 diabetes and that 25.9% of Americans 65 years of age or greater will have diabetes.


About ARKRAY USA, Inc.

ARKRAY USA, Inc. is a division of ARKRAY, a global leader in diabetes care with headquarters in Kyoto, Japan. For more than half a century, ARKRAY has pioneered products to ensure that people who have diabetes - and the health professionals who care for them - can better manage the condition. ARKRAY currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the U.S. The Company has a long history of developing cutting edge technology such as the first portable glucose analyzer available in the United States; the first HbA1C analyzer; and the first hand-held blood glucose meter. For more information, visit